



October 13, 2017

Sub: Elaboration on the expenses mentioned in the outcome of

Board Meeting held on October 12, 2017

Pursuant to the intimation given by the Company to the Stock Exchanges vide its letter dated October 12, 2017 subsequent to the meeting of the Board of Directors held today, the Company has received certain queries on the expenses and costs aggregating to Rs. 1,537 crores relating to the Transactions, and would like to clarify the following break-up of the said expenses and costs:

- Transaction taxes and expenses: Rs. 877 crores (24% of the Gross Realization of Rs. 3,614 crores);
- Incentives to employees and key managerial personnel: Rs. 300 crores (8% of the Gross Realization);
- The remaining Rs. 360 crores primarily relates to contingent liabilities of which Rs. 146 crores already disclosed in the annual report and additional provision for contingencies on account of Regulatory, Litigations and any other liabilities and payments towards outstanding liabilities.

Thanking You.

Yours faithfully,

FOR CLARIS LIFESCIENCES LIMITED

Chandrasingh Purohit
WHOLE TIME DIRECTOR & CFO



Claris Lifesciences Limited

Claris Corporate Headquarters, Nr. Parimal Rly. Crossing,
Ellisbridge, Ahmedabad 380 006, India.
Tel: +91-79-26563331, 66309339 Fax: +91-79-26408053
www.clarislifesciences.com

(Corporate Identity Number: L85110GJ1994PLC022543)

f /claristd | in /company/claris-lifesciences-limited